Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial
Top Cited Papers
- 20 January 2011
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 377 (9764) , 477-486
- https://doi.org/10.1016/s0140-6736(10)62050-8
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Combination therapy for visceral leishmaniasisThe Lancet Infectious Diseases, 2010
- Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in IndiaNew England Journal of Medicine, 2010
- Of Cattle, Sand Flies and Men: A Systematic Review of Risk Factor Analyses for South Asian Visceral Leishmaniasis and Implications for EliminationPLoS Neglected Tropical Diseases, 2010
- Membrane sterol depletion impairs miltefosine action in wild-type and miltefosine-resistant Leishmania donovani promastigotesJournal of Antimicrobial Chemotherapy, 2009
- Injectable Paromomycin for Visceral Leishmaniasis in IndiaNew England Journal of Medicine, 2007
- Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome?Microbes and Infection, 2007
- Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980–2004The Lancet Infectious Diseases, 2005
- Drug resistance in Indian visceral leishmaniasisTropical Medicine & International Health, 2001
- Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial Commentary: cost and resistance remain issuesBMJ, 2001
- Failure of Pentavalent Antimony in Visceral Leishmaniasis in India: Report from the Center of the Indian EpidemicClinical Infectious Diseases, 2000